
|Slideshows|March 2, 2016
Neuro News Roundup: Multiple Sclerosis
Author(s)Mark L. Fuerst
Risk factors regarding MS, including genetic research findings and progressive multifocal leukoencephalopathy while taking natalizumab, are discussed.
Advertisement
New recommendations aim to reduce the risk for progressive multifocal leukoencephalopathy (PML) with use of natalizumab in patients with relapsing remitting multiple sclerosis (RRMS). RRMS patients taking natalizumab who seroconvert to high levels of signaling antibodies are at increased risk of PML. In a new finding, seven loci have been added to the list of genuine MS genetic risk factors.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis
2
Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease
3
Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook
4
CMSC 2026: Looking Ahead to the 40th Annual Meeting of the Consortium of MS Centers
5




















